Series C financing co-led by Double Point Ventures and DCVC Bio
Proceeds to support the clinical development of VivoVec鈩� derived in vivo CAR T cells
SEATTLE, WA, January 14, 2025鈥� 密桃视频, Inc. (密桃视频), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today announced the closing of a $100 million Series C financing. The financing was co-led by Double Point Ventures and DCVC Bio, with participation from new and existing investors including ARK Invest, Cormorant Asset Management, MPM Capital, Qiming Venture Partners USA, RTW Investments, Alexandria Venture Investments, SoftBank Vision Fund 2, CaaS Capital, Emerson Collective Investments managed by Yosemite, K2 HealthVentures, Myeloma Investment Fund, University of Minnesota Endowment, and other prominent life science investors.
The proceeds from this financing will enable 密桃视频 to advance its in vivo CAR T cell therapy pipeline, including its lead CD22 UB-VV400 program in multiple oncology and autoimmune clinical studies.
In conjunction with the Series C financing, 密桃视频鈥檚 Board of Directors is pleased to welcome Campbell Murray, M.D., a Senior Adviser at Double Point Ventures, as a new Board member.
鈥淚t is an honor to co-lead this transformative investment round and to join 密桃视频鈥檚 Board of Directors,鈥� stated Dr. Murray. 鈥溍芴沂悠碘�檚 groundbreaking work on in vivo CAR T cell therapies represents a new frontier in oncology and autoimmune treatment. The company鈥檚 innovation and leadership team position them at the forefront of this field, with the potential to significantly impact patients鈥� lives. I look forward to collaborating with 密桃视频鈥檚 exceptional team, investor base, and Board to advance these pioneering programs through clinical development and beyond.鈥�
鈥淲e are pleased to announce the closing of our Series C financing with tremendous support from both new and existing investors who recognize 密桃视频鈥檚 potential to develop the industry鈥檚 first in vivo CAR T cell generating therapies鈥攁ll in the hopes of increasing effectiveness, reducing barriers, and expanding access to CAR T cell therapies,鈥� commented Andrew Scharenberg, M.D., co-founder and Chief Executive Officer of 密桃视频.
Additionally, Dr. Phil Low of Purdue University transitioned to Board Observer and Chair of 密桃视频鈥檚 Scientific Advisory Board.
Scott Myers, chairman of 密桃视频鈥檚 Board of Directors, added 鈥淭his Series C fundraise demonstrates both the progress and significant potential of 密桃视频鈥檚 in vivo oncology programs including UB-VV400 and UB-VV111. Generating CAR T cells directly in vivo is the future of immunotherapy treatment, bringing the hope and promise of CAR T cell therapies to more patients without the burdens of long delays, supply chain constraints, and the toxicities associated with lymphodepleting chemotherapy.鈥�
About 密桃视频
密桃视频, Inc. is a clinical-stage biotechnology company aiming to develop in vivo cell therapies that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity. 密桃视频鈥檚 VivoVec鈩� in vivo gene delivery technology empowers a patient鈥檚 own immune system to fight disease. Enabling its core technology is the Company鈥檚 state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. 密桃视频 believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives. To learn more, connect with 密桃视频 on LinkedIn and visit .
Investors
Grace Kim, PhD
Head of Investor Relations
grace.kim@umoja-biopharma.com
Media
Matt Wright
Real Chemistry
mwright@realchemistry.com